Innovative BBB Assays HUREL, now part of Visikol, has developed advanced in vitro BBB permeability assays and models, presenting opportunities to collaborate with pharma and biotech companies focused on drug delivery and CNS therapeutics seeking reliable permeability testing solutions.

Multiplex Imaging Services The recent launch of multiplex tissue imaging in a GLP setting demonstrates Visikol’s capability in high-throughput, high-content imaging, which can be leveraged by clients in pharmacology and pathology research requiring precise tissue analysis.

Tissue Slice Models Visikol’s suite of precision cut tissue slices including human and animal kidney and liver tissues offers targeted opportunities for companies involved in toxicology, drug metabolism, and disease modeling needing ex vivo tissue testing platforms.

Strategic Partnerships Collaborations with industry leaders like Standard BioTools enhance Visikol's imaging portfolio, indicating a vendor capable of supporting complex imaging and cytometry requirements for clients developing multi-marker tissue analysis.

Growth and Funding With revenues between 10 and 25 million dollars, Visikol shows significant market presence and growth potential, making it a promising partner for biotech firms seeking innovative research services and cutting-edge in vitro models.